Update on Hepatitis C Treatment

, Clinical Instructor, UCLA School of Medicine, Los Angeles, California, and , Medical Director, Liver Transplantation, Cedars-Sinai Medical Center, Associate Professor of Medicine, UCLA School of Medicine, Los Angeles, California


February 15, 2001

In This Article


Treatment options for HCV infection continue to expand. Whereas SRs of 10% were achieved with IFN monotherapy only several years ago, it may soon be possible to achieve SR rates greater than 50% with combination pegylated IFN and ribavirin. Molecular-based, specific therapeutic strategies are also likely to become a reality in the future, although therapy will remain interferon-based the next several years.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.